Advanced search
Publication Cover
Patient Preference and Adherence Volume 13, 2019 - Issue
Submit an article Journal homepage
92
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections

Johanna MuckePoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8915-7837
ORCID Icon,
Ralph BrinksPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
,
Rebecca Fischer-BetzPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
,
Jutta G RichterPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
,
Oliver SanderPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, GermanyORCID Iconhttps://orcid.org/0000-0001-5196-9370
ORCID Icon,
Matthias SchneiderPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
&
Gamal ChehabPoliclinic and Hiller Research Unit for Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, GermanyORCID Iconhttps://orcid.org/0000-0001-7309-2370
ORCID Icon show all
Pages 1889-1894 | Published online: 04 Nov 2019

References

  • Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-221296403
  • Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019;78(3):372–379. doi:10.1136/annrheumdis-2018-21404330610066
  • Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–2337. doi:10.1002/art.3440022275291
  • Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–844. doi:10.1136/annrheumdis-2012-20286523524886
  • Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2017;69(5):1016–1027. doi:10.1002/art.40049
  • Ramachandran S, Parks D, Kurtinecz M, Roth DA, Alfonso-Cristancho R. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. J Comp Eff Res. 2018;7(6):581–593. doi:10.2217/cer-2017-008529692179
  • Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018;27(9):1489–1498. doi:10.1177/096120331877763429807477
  • Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49(2):289–294. doi:10.1093/rheumatology/kep35419920093
  • Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S. Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient. 2018;11(1):119–129. doi:10.1007/s40271-017-0276-228956281
  • Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1–14. doi:10.1002/(ISSN)1557-068117726671
  • Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–99. doi:10.2147/PPA.S5515624470758
  • Desplats M, Pascart T, Jelin G, et al. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol. 2017;36(6):1395–1400. doi:10.1007/s10067-017-3587-828255739
  • Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.3061322127708

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.